Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
 
 
 
A RANDOMIZED, DOUBLE-BLIND, VE HICLE-CONTROLLED, EFFICACY AND 
SAFETY STUDY OF OLUMACOSTAT GL ASARETIL GEL IN SUBJECTS WITH 
ACNE VULGARIS 
 
Protocol Number DRM01B-ACN04 
Protocol Final Date [ADDRESS_1199967] 
 Menlo Park, CA [ZIP_CODE] 
 [LOCATION_003] 
 
CONFIDENTIAL INFORMATION 
The information contained herein is conf idential and the propri etary property of 
Dermira. Any use or disclosure of such information without the prior written 
authorization of Dermira is expressly prohibited. 
 
06 October 2016 Page 1 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
A RANDOMIZED, DOUBLE-BLIND, VE HICLE-CONTROLLED, EFFICACY  
AND SAFETY STUDY OF OLUMACOSTAT GLASARETIL GEL IN  
SUBJECTS WITH ACNE VULGARIS 
CRO Personnel 
TKL Research  Name: [CONTACT_294745]: Project Director 
Tel: [PHONE_6127], ext 5140 
Mobile: [PHONE_6128] 
Email: [EMAIL_5794] 
SAE/Emergency Contact [CONTACT_294714]: Jubin Ryu, MD Title: Medical Monitor 
Mobile: +[PHONE_6129]  
Fax: +[PHONE_6130] 
Email: [EMAIL_5795] 
Sponsor Personnel  
Dermira  Name: [CONTACT_294746]: Clinical Lead 
Tel: +[PHONE_6131] 
Mobile: +[PHONE_6132] 
Fax: +[PHONE_6130] 
Email: [EMAIL_5796] 
 
06 October 2016 Page 2 Confidential 
Dermira, Inc.
Olumacostat Glasaretil Gel DRMOlB-ACNO4
SPONSOR SIGNATURE [CONTACT_1783]
A RANDOMTZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, EF'FICACY
AND SAFETY STUDY OF OLUMACOSTAT GLASARETIL GEL IN
SUBJECTS WITH ACNE VULGARIS
Protocol Number DRMOlB.ACNO4
Protocol Final Date [ADDRESS_1199968] the authority to
approve this protocol on behalf of the Sponsor, Dermira, Inc. The study will be conducted in
accordance with this protocol and all applicable laws, rules, and regulations and with the
International Conference on Harmonisation Good Clinical Practice (ICH GCP), regulations of
Canada and the [LOCATION_002] (US) Food and Drug Administration (FDA) and the ethical
principles that have their origin in the Declaration of Helsinki.
Authorized by:
[CONTACT_860809]Ð br/
Sponsor Signature
[CONTACT_294747] A. Bauer, MD
Chief Medical OfficerDate (DD MMM YYYY)
[ADDRESS_1199969] their origin  in the Declaration of Helsinki, International 
Conference on Harmonisation (ICH) Guidelines for Good Clinical Practice (GCP) and applicable 
laws, rules and regulatory requirement(s) including those of Canada and the [LOCATION_002] (US) 
Food and Drug Administration (FDA). 
I agree to obtain the Institutional Review Bo ard (IRB)/Independent Et hics Committee (IEC) 
approval of the protocol and informed c onsent prior to the start of the study. 
I agree to obtain formal written informed consen t in accordance with applicable federal and local 
regulations and international gui delines from all subjects prio r to their entry into the study. 
I have received and reviewed th e Investigator’s Brochure includi ng the potential risks and side 
effects of the product and instructions for use. 
I agree to report to the Sponsor any adverse events that occu r during the course of the study in 
accordance with the ICH GCP guideline and the protocol. 
I agree to ensure that all associates, colleagues,  and employees assisting me with the conduct of 
the study are informed of their responsibilitie s in meeting the above commitments and the 
commitments set forth in the Investigator’s Agreement. 
I agree to maintain adequate and accurate reco rds and to make those records available for 
inspection in accordance with the ICH GCP guideline, and federal and local requirements. I understand that the study may be terminated or enrollment suspended at any time by [CONTACT_429], with or without cause, or by [CONTACT_294715]. 
 
 _____________________________________ ________________________ 
Investigator’s Signature [CONTACT_1782] (DD MMM YYYY) 
  _____________________________________ 
Investigator’s Name (print) 
06 October 2016 Page 4 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
PROTOCOL SYNOPSIS 
Title: A Randomized, Double-Blind, Vehicle-Controlled, Efficacy and Safety Study of 
Olumacostat Glasaretil Gel in Subjects with Acne Vulgaris  
Protocol Number: DRM01B-ACN04 
Phase: 3 
Number of Sites: Approximately 50 
Study Population Subjects ≥ 9 years of age with acne vulgaris  
Sample Size Approximately 700 subjects 
Study Treatment Olumacostat Glasaretil Gel, 5.0%,  applied twice daily 
Olumacostat Glasaretil Gel, Vehicle, applied twice daily 
Randomization 2:1 (active:vehicle) 
Study Objective: To assess the efficacy and safety of Olumacostat Glasaretil Gel, 5.0% compared to Olumacostat Glasaretil Gel, Vehicle wh en applied twice daily to the face for 
[ADDRESS_1199970] Participation: • Screening: maximum duration of 35 days  
• Treatment period: 12 weeks 
Maximum total participation: 17 weeks  
Study Visit Schedule Screening, Baseline/Day 1, Weeks 1, 2 (phone call), 4, 8, 12 (Exit)  
Study Design/Summary: 
This study is a randomized, double-blind, vehicle-controlled, parallel group study, designed to assess the 
efficacy and safety of Olumacostat Glasaretil Gel, 5.0% compared to Olumacostat Glasaretil Gel, Vehicle 
in subjects with acne vulgaris on the face. All subject s will sign an informed co nsent or assent (pediatric 
subjects) and undergo screening for study eligibility.  
Approximately 700 eligible subjects, ≥ 9 years of age, will be randomized, in a 2:1 fashion, to 
Olumacostat Glasaretil Gel, 5.0%  or Olumacostat Glasaretil Gel, Vehicle treatment, respectively. Study 
drug will be applied twice daily to the face for 12 w eeks. Subjects will return to the study clinic at 
Weeks 1, 4, 8 and 12 (Study Exit). A follow-up ph one call at Week 2 will be made to assess safety 
(adverse events) only.  Primary efficacy will be assessed through acne lesion counts (inflammatory and non-inflammatory 
lesions) and investigator global assessment of acn e (IGA). All efficacy endpoints will be assessed from 
baseline to Week 12.  
Safety will be assessed through adverse events, local sk in reactions (LSRs), serum chemistry, hematology 
and urinalysis laboratory testing, ECG testi ng, physical examination and vital signs. 
Photographs of the face will be taken in all subjects at  a subset of sites in order to visually assess the 
appearance of acne vulgaris during the course of the study. During clinic visits, subjects will be asked to 
complete Acne Patient Self-Questionnaire.  
[ADDRESS_1199971] Statement ..........................................................................................13  
2 STUDY SUMMARY...........................................................................................................14  
3 STUDY OBJECTIVES ......................................................................................................14  
4 STUDY ENDPOINTS ........................................................................................................14  
5 STUDY DESIGN ................................................................................................................15  
5.1 Duration of the Study ................................................................................................15  
5.2 Study Population and Number of Subjects ...............................................................15  
5.3 Selection of Subjects .................................................................................................15  
5.3.1 Inclusion Criteria ..........................................................................................15  
5.3.2 Exclusion Criteria .........................................................................................15  
5.3.3 Females – Non-childbearing Potential ..........................................................17  
5.3.4 Females – Childbearing Potential .................................................................[ADDRESS_1199972] ............................................................................17  
6.2 Packaging, Labeling and Storage ..............................................................................18  
6.3 Treatment Assignment ..............................................................................................18  
6.4 Study Drug Dispensing and Return ..........................................................................18  
6.5 Study Drug Application ............................................................................................19  
6.6 Treatment Compliance ..............................................................................................19  
6.7 Study Drug Accountability .......................................................................................20  
7 CONCOMITANT MEDICATIONS AND PROCEDURES ...........................................20  
7.1 Permitted Treatments and Procedures ......................................................................20  
7.2 Prohibited Treatments and Procedures .....................................................................20  
8 STUDY PROCEDURES ....................................................................................................21  
8.1 Screening (Day -35 to -1) .........................................................................................21  
8.2 Baseline Visit/ Day 1 ................................................................................................22  
8.3 Week 1 (+/-2 days) ...................................................................................................[ADDRESS_1199973] (+/-2 days) ....................................................................23  
8.5 Week 4 (+/-4 days) ...................................................................................................23  
8.6 Week 8 (+/-4 days) ...................................................................................................23  
8.7 Week 12 (+/-4 days) Study Exit or Early Termination Visit ....................................24  
8.8 Unscheduled Visits ...................................................................................................24  
9 DETAILS OF ASSESSMENTS .........................................................................................24  
9.1 Screening Assessments .............................................................................................25  
9.1.1 Demographics ...............................................................................................25  
06 October 2016 Page 6 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
9.1.2 Medical History ............................................................................................25  
9.1.3 Disease Specific Information ........................................................................25  
9.2 Assessment of Efficacy .............................................................................................25  
9.2.1 Investigator Global Assessment ....................................................................25  
9.2.2 Acne Lesion Count .......................................................................................26  
9.3 Other Assessments ....................................................................................................26  
9.3.1 Photographs...................................................................................................26  
9.3.2 Acne Patient Self-Questionnaire ...................................................................27  
9.4 Assessment of Safety ................................................................................................27  
9.4.1 Physical Examination....................................................................................27  
9.4.2 Vital Signs .....................................................................................................27  
9.4.3 ECGs .............................................................................................................27  
9.4.4 Laboratory Evaluations .................................................................................28  
9.4.5 Local Skin Reactions (LSRs) ........................................................................28  
9.4.6 Adverse Events .............................................................................................29  
9.4.7 Serious Adverse Events ................................................................................30  
9.4.8 Dosing Changes due to AEs .........................................................................32  
9.4.9 Pregnancy ......................................................................................................32  
10 STUDY DISCONTINUATIONS .......................................................................................33  
10.1 Discontinuation of the Study ....................................................................................33  
10.2 Early Study Termination of Study Subjects..............................................................33  
10.3 Study Drug Discontinuation .....................................................................................34  
11 STATISTICAL CONSIDERATIONS ..............................................................................34  
11.1 General Statistical Methodology...............................................................................34  
11.2 Populations Analyzed ...............................................................................................35  
11.3 Primary Efficacy .......................................................................................................35  
11.4 Secondary Efficacy ...................................................................................................36  
11.5 Other Supportive Efficacy Analyses .........................................................................36  
11.6 Pooling Analysis .......................................................................................................37  
11.7 Missing Efficacy Data Imputations ..........................................................................38  
11.8 Sensitivity Efficacy Analyses ...................................................................................40  
11.9 Subgroup Analyses ...................................................................................................41  
11.10 Exposure and Compliance ........................................................................................41  
11.11 Adverse Events .........................................................................................................42  
11.12 Local Skin Reactions ................................................................................................42  
11.13 Other Safety Data ......................................................................................................42  
11.14 Sample Size Determination .......................................................................................43  
12 STUDY ADMINISTRATION ...........................................................................................44  
12.1 Compliance with the Protocol ...................................................................................44  
12.2 Informed Consent Procedures ...................................................................................44  
12.3 Study Documentation and the Electronic Case Report Form ...................................45  
12.4 Study Monitoring ......................................................................................................45  
12.5 Retention of Study Documentation ...........................................................................46  
13 ACRONYMS AND DEFINITIONS ..................................................................................46  
13.1 Acronyms ..................................................................................................................46  
06 October 2016 Page 7 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
14 REFERENCES ...................................................................................................................4 8 
15 APPENDIX 1 – SCHEDULE OF EVENTS .....................................................................49  
16 APPENDIX 2 – ACNE PATIENT SELF- QUESTIONNAIRE .....................................[ADDRESS_1199974] OF TABLES  
Table 1: Fitzpatrick Skin Type .................................................................................................. 25  
Table 2: Investigator Global Assessment .................................................................................. 26  
Table 3: Subject Assessed Local Skin Reactions ...................................................................... 29  
Table 4: Investigator Assessed Lo cal Skin Reactions ............................................................... [ADDRESS_1199975] Development Rationale 
Acne arises from a combination of physiological changes in the sk in including altered sebaceous 
gland cell differentiation, height ened sebum production, localized  bacterial colonization and 
inflammation. Although acne is generally viewed  as a benign dermatological disease of 
adolescence, more severe forms may lead to permanent scar formati on, with some of these 
patients suffering from psychological injury and si gnificant loss of self-wor th. Recent scientific 
advances in the understanding of the complex multi-factorial nature  of this common disease offer 
great opportunity for scientific innovation through selective targ eting of key elements of the 
disease process. 
Sebum is a waxy/oily substance comprised of choles terol, fatty acids, fatty  alcohols, triglycerides 
(TGs), wax esters, sterol esters and squa lene produced by [CONTACT_294716] [ 1]. Sebaceous 
glands are associated with hair follicles. The basal layer of sebocytes just inside the basement 
membrane consists of small, nucleated cells devo id of lipid droplets. This layer contains the 
dividing cells that replenish the gl and as cells are lost in the pr ocess of holocrine rupture. As 
cells move from the basal layer towards the cente r of the gland, they differentiate and produce 
lipi[INVESTIGATOR_294688]. Eventually th e cells become distended with lipid droplets and 
the nuclei and other sub-cellular st ructures disappear. As the cells  approach the sebaceous duct, 
they disintegrate and release thei r contents through holocrine secr etion. In acne, diglycerides and 
free fatty acid levels may be increased by [CONTACT_50904] l degradation of diglycer ides and triglycerides 
present within sebum. Free fatty acids may promote inflammatory response in acne by [CONTACT_294717]-inflammatory factors. 
A direct correlation between the degree of acne improvement and the extent of sebum reduction 
produced by [CONTACT_294718]-acne medications has been established [2]. The oral retinoid 
13-cis-retinoic acid (13-cis-RA, Accutane®) is particularly eff ective at reducing sebum 
output although its mode-of-action is not likely related to a dire ct effect on sebum synthesis 
pathways [ 3]. 
Topi[INVESTIGATOR_294689], in cluding antibiotics, retinoids and combinations 
thereof, often produce only modest therapeutic benefits and do not affect sebum production. A 
locally-delivered medication that selectively inhibited sebum formation would represent a 
breakthrough advance in reduci ng the pathogenic influences of sebum overproduction in acne. 
Acetyl-coenzyme A carboxylases (A CCs) have crucial roles in fatty acid metabolism in humans 
and most other living organisms [ 4]. ACC catalyzes the carboxylat ion of acetyl-CoA to form 
malonyl-CoA. This is the first committed step in  fatty acid biosynthesis and is the rate limiting 
reaction for the pathway [ 5, 6, 7]. These fatty acids then can be stored or converted to 
triglycerides (TGs) and phospholip ids. In addition to its role as a substrate in fatty acid 
biosynthesis, malonyl-CoA, also plays an important  regulatory role in controlling mitochondrial 
fatty acid uptake through allosteric inhibition of carnitine palmitoyltran sferase I (CPT-I), the 
enzyme catalyzing the first committed step  in mitochondrial fatty acid oxidation [ 8]. Malonyl-
CoA, therefore, is a key metabolic signal for the control of fatty acid pr oduction and utilization 
in response to dietary changes and altere d nutritional requirements in animals [ 6]. As a result of 
06 October 2016 Page 9 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
its unique position in intermediary metabolism, i nhibition of ACC offers the ability to inhibit 
de novo fatty acid production in lipogenic tissues, su ch as liver, adipose tissue, and sebaceous 
glands. 
A variety of structurally diverse ACC inhibitors has recently been described in the scientific and 
patent literature for potential use in metabolic syndrome. One class of ACC inhibitors, including 
TOFA (5-(tetradecyloxy)-2-furancarboxylic acid), consists of lipophilic fatty acid mimetics that 
compete with acetyl-CoA in the ACC-mediated formation of malonyl-CoA. Investigators have 
demonstrated that TOFA reduced fatty acid synthe sis and TG secretion bo th in cultured hepatic 
cells [ 8, 10] and in experimental animals [11, 12 ], reduced plasma cholesterol and TGs in 
experimental animals including rhesus monkeys [ 10, 11], and reduced body weight [ 13]. 
The ability to deliver TOFA topi[INVESTIGATOR_294690] a means to inhibit de novo fatty acid 
production in sebaceous glands, introducing a new treatment paradigm for acne vulgaris.  
1.2 Summary of Investigational Program 
Dermira, Inc. is pursuing the development of olumacostat glasaretil, previously referred to as DRM01B, a pro-drug of TOFA, sarc osine ester, as a topi[INVESTIGATOR_897] a pplied sebum inhibitor for the 
treatment of acne vulgaris. Olumacostat glasaretil  is hydrolyzed by [CONTACT_294719], TO FA. TOFA is converted to Tofyl-CoA intracellularly, which 
competes with acetyl-CoA in the ACC-mediat ed formation of malonyl-CoA. As a result, 
inhibition of malonyl-CoA synthe sis offers a means to inhibit de novo fatty acid production in 
the sebaceous glands in subjects with  acne vulgaris. Olumacostat glasaretil  is a new chemical 
entity and has been formulated for clinical development as Olumacostat Glasaretil Gel, 5.0%.   
A summary of clinical and nonclinical pharmacology, toxicol ogy and metabolism data is 
presented below. Detailed information is provi ded in the current Investigator’s Brochure. 
Safety pharmacology studies were conducted wi th olumacostat glasaretil administered 
intravenously (IV) which included neurobehavioral and pulmonary function studies in rats and a 
cardiovascular study in telemetered minipi[INVESTIGATOR_14107]. These studies revealed no adverse findings 
attributable to olumacostat glas aretil. In vitro studies assessing the effects of olumacostat 
glasaretilel and TOFA upon huma n ether-à-go-go-related gene (hERG) ionic conductance in 
human embryonic kidney (HEK) cells also reveal ed no significant inhibition at the maximum 
concentrations tested. Overall,  the results from the safety pharmacology showed no adverse 
effects at exposures to parent drug and/or TOFA several orders of  magnitude beyond that 
anticipated to be seen following topi[INVESTIGATOR_294691]. 
Following IV administration in rats and minipi[INVESTIGATOR_14107], olumacost at glasaretil was quickly 
metabolized to TOFA; no evidence of any ge nder-specific differences or accumulation upon 
repeated dosing of either olumaco stat glasaretil or TO FA was observed. With oral administration 
in rats, low ng/mL levels of olumacostat glasaretil were noted while exposure to TOFA reached 
levels exceeding 1 µg/mL. In vitro metabolism a nd plasma protein binding experiments indicated 
that olumacostat glasaretil was metabolized a nd bound to plasma protein in a similar manner 
between humans and the species utilized for toxicology and safety pharmacology assessments 
(rat and minipig).  
06 October 2016 Page 10 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
Toxicokinetic assessments conducted following the topi[INVESTIGATOR_294692]; 
peak plasma levels recorded in these studies were below the detectable limit for olumacostat 
glasaretil and while TOFA was detectable following application of the highest strength of 
Olumacostat Glasaretil Gel (7.5% w/w), mean values did not exceed 6 ng/mL for TOFA. The 
test article used in this study is the same form ulation and concentration that was used in the 
clinical proof of concept study (DRM01B-ACN01) and the same form ulation that was one of the 
strengths included in the clinical dose ranging trial (DRM01B-ACN02).  
Toxicology studies conducted with olumacostat glasaretil included de rmal studies in minipi[INVESTIGATOR_294693] [ADDRESS_1199976] udy, aside from histological fi ndings associated with the non-
glandular stomach (fore-stomach) in the 13-week rat oral study. This finding was considered a 
direct local effect (not due to systemic absorp tion), reversible and non-adverse, and is of doubtful 
clinical relevance given the abse nce of this structure in humans. In the other toxicology studies, 
there were no remarkable olumacostat glasaretil -related findings and ol umacostat glasaretil was 
well tolerated. No adverse systemic  effects were associated with mean peak plasma exposures to 
olumacostat glasaretil and TOFA up to 9955 and 3630 ng/mL, respectively, which are 
concentrations exceeding 4000-fold that seen fo llowing the dermal application of maximum 
feasible doses (10 mg/kg) to minipi[INVESTIGATOR_14107]. In vivo a nd in vitro studies conducted to assess dermal 
sensitization, ocular irritation, and phototoxicity did not reveal any remarkable effects following 
the exposure of cells/tissues to olumacostat glas aretil. Genetic toxicology results indicated that 
olumacostat glasaretil was neither  mutagenic nor clastogenic. Pr edictive software assessments 
indicated there were no potential  theoretical manufacturing impuritie s or metabolic products that 
were of mutagenic concern. Ov erall, the results of the nonc linical toxicology and safety 
pharmacology studies suggest the safety risks po sed by [CONTACT_294720]. 
Two clinical studies, DRM01B-ACN01 and DRM01B-ACN02, have been completed as part of 
the Phase 2 development program. DRM01B-A CN01 was a proof of concept study which 
assessed the safety and efficacy of one strength  of Olumacostat Glasaretil Gel compared to 
vehicle gel in adult subjects with acne vul garis. DRM01B-ACN02 was a dose ranging study 
which assessed the safety and efficacy of mu ltiple strengths and regimens of Olumacostat 
Glasaretil Gel and vehicle gel in  adult subjects with acne vulgar is. In both studies, Olumacostat 
Glasaretil Gel was shown to be well-tolerated  and demonstrated statistically significant 
improvements in acne lesions counts and sever ity. Additional information on these studies is 
provided below.  
Study DRM01B-ACN01 
DRM01B-ACN01 was randomized, vehicle controlle d, parallel group study designed to assess 
the safety and tolerability of Olumacostat Glasar etil Gel, 7.5% in healthy volunteers (Phase 1) 
before assessing the safety, tolerability and prelim inary efficacy of the drug in subjects with acne 
vulgaris (Phase 2a). In the Phase 1 portion of the study, 6 healthy volunteers applied study 
Olumacostat Glasaretil Gel twice daily, to the face, for one week. Review of the data from 
06 October 2016 Page 11 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
Phase 1 showed that Olumacostat Glasaretil Gel was well tolerated with no safety concerns. As 
such, the Phase 2a portion of  the study was conducted. 
In the Phase 2a portion of the study, Olumacostat Glasaretil Gel was applied, twice daily, to the 
face in 108 adult subjects with acne vulgaris fo r a 12–week treatment period. Similar to Phase 1, 
Olumacostat Glasaretil Gel was we ll tolerated with most AEs reported as mild to moderate in 
severity. Subjects treated with Olumacostat Glasaretil Gel had si gnificantly greater reductions in 
inflammatory and noninflammatory lesion counts  from Baseline to Week 12 compared with 
subjects treated with vehicle gel.  In addition, a significantly greater  proportion of subjects treated 
with Olumacostat Glasaretil Gel had a successful  improvement in IGA score (corresponding to 
less severe acne) than subjects treated with vehicle gel.  
Study DRM01B-ACN02 
Study DRM01B-ACN02 was a Phase 2 dose-ranging study in adult subjects with acne vulgaris 
on the face. The study was a randomized, vehicle controlled, parallel group study designed to 
assess the efficacy and safety of Olumacostat Glasaretil Gel at a concentration of 7.5% BID, 
7.5% QD, and 4.0% QD, compared to vehicle BID or  QD in subjects with moderate to severe 
facial acne.  
A total of 420 adult subjects were randomized to active and vehicle in a 2:2:2:1:1 fashion. Study 
treatments continued for 12 weeks. Subjects returned to the study clinic at Weeks 1, 2 (phone 
call only), 4, 8 a nd 12 (study exit).  
The results of the study showed that all three Olumacostat Glasaretil Gel treatment groups 
demonstrated statistically signifi cantly greater reductions in the absolute change in inflammatory 
lesion counts from baseline to Week 12 than the combined vehicle group. The LS mean changes 
in inflammatory lesion counts were −14.6 and − 14.5, and − 15.0 for the Olumacostat Glasaretil 
Gel, 4.0% QD, 7.5% QD, and 7.5% BID gr oups, respectively, compared with −10.7 for the 
combined vehicle QD group (P = 0.011, P = 0.014, and P = 0.011 respectively). All 3 Olumacostat Glasaretil Gel treatment groups showed statistically significantly greater 
reductions in the absolute change in noninflamm atory lesion counts from baseline to Week 12 
than the combined vehicle group. The LS mean changes in noninflammatory lesion counts at 
Week 12 were −15.3, − 13.4, and −17.5 for the DRM01B Olumacostat Glasaretil Gel 4.0% QD, 
7.5% QD, and 7.5% BID groups, re spectively, compared with −9.3 for the combined vehicle 
group (P = 0.004, P = 0.050, and P < 0.011 respectively).  
The Olumacostat Glasaretil Gel 4.0% QD and 7.5% BID groups each had a statistically 
significantly greater proportion of subjects achieve a minimum 2-grade improvement (reduction) 
in IGA score from baseline at Week 12 compar ed with the combined vehicle group. The percent 
of subjects achieving this endpoint was 21.6% in  the Olumacostat Glasaretil Gel 4.0% QD and 
25.9% of subjects in the Olumaco stat Glasaretil Gel 7.5% BID group (compared with 9.8% in 
the combined vehicle QD group (P = 0.024 and P = 0.004, respectively). 
06 October 2016 Page 12 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
Pharmacokinetic (PK) results, assessed in a subset of subjects, showed that plasma 
concentrations of Olumacostat Glasaretil Gel on Day [ADDRESS_1199977], 
who had a plasma concentration of 0.304 at 1 time point ([ADDRESS_1199978]-dosing). Plasma 
concentrations of Olumacostat Gl asaretil Gel at Week [ADDRESS_1199979] subjects, but detectable in a 
few subjects in each dose group, with values  ranging from 0.101 to 1.02 ng/mL. Plasma 
concentration of TOFA at Week [ADDRESS_1199980] subjects in the DRM01B QD dose 
groups, but detectable in a fe w subjects, with values ranging from 0.100 to 0.299 ng/mL. In the 
Olumacostat Glasaretil Gel, 7.5% BID group, appr oximately half of the tested subjects had 
detectable TOFA levels at each time point, with mean values ranging from 0.156 to 
0.340 ng/mL. 
The most common AEs reported du ring the study were nasopharyngi tis, upper respi[INVESTIGATOR_4348], and application site pr uritus. Most AEs were mild or moderate in severity. Erythema 
was the most common LSR. Laboratory values, vita l signs, and ECGs measured at the end of the 
study were generally consistent with baseline values, with no clinically significant trends. 
There were no deaths during th e study however, one subject in the 7.5% QD group had an SAE 
of uterine leiomyoma considered unrelated to treatment. Seven subjects prematurely 
discontinued study drug due to an AE, [ADDRESS_1199981] shown that Olumacostat Gl asaretil Gel was well tolerated at multiple 
concentrations. Olumacostat Glasaretil Gel at a strength of 5.0% has been selected as the 
concentration to take forward in Phase 3 developm ent. Two Phase 3 pi[INVESTIGATOR_294694] 3 development program and w ill include adults and adolescents (ages 9 years 
and older) in order to confirm the efficacy and sa fety of Olumacostat Glasaretil Gel, 5.0% for the 
treatment of acn e vulgaris.  
This study, DRM01B-ACN04, is one of the two conf irmatory Phase 3 trials being conducted to 
assess the efficacy and safety of Olumacostat Glasar etil Gel, 5.0% in subjects with acne vulgaris. 
1.[ADDRESS_1199982] Statement 
This study will be conducted in compliance with the protocol, according to current [LOCATION_002] 
federal regulations (Title 21, Code of Fe deral Regulations [CFR] Parts 11, 50, 54, 56,312, and 
314 as appropriate) and the prin ciples of the International Conference on Harmonisation (ICH) 
(ICH E6 1997) Good Clinical Practice (GCP), F ood and Drug Administration (FDA) guidelines, 
Canadian guidelines and the D eclaration of Helsinki, 1964 (as amended in Edinburgh [2000]). 
06 October 2016 Page 13 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
2 STUDY SUMMARY  
This study is a randomized, double- blind, vehicle-controlled, para llel group study, designed to 
assess the efficacy and safety of Olumacostat Glasaretil Gel,5.0% compared to Olumacostat 
Glasaretil Gel, Vehicle in subjects with acn e vulgaris on the face. A ll subjects will provide 
informed consent or assent (p ediatric subjects) and undergo screening for study eligibility.  
Approximately 700 eligible subjects ≥ 9 years of age will be randomized, in a 2:1 fashion, to 
Olumacostat Glasaretil Gel, 5.0% or Olumacostat Glasaretil Gel,  Vehicle treatment, respectively. 
Study drug will be applied twice da ily to the face. Subjects will re turn to the study clinic at 
Weeks 1, 4, 8 and 12 (Study Exit). A follow-up phone call at Week 2 will be made to assess 
safety (adverse events) only.  
Primary efficacy will be assessed through acne lesion counts (inflammatory and non-
inflammatory lesions) and investigator global assessment of acne (IGA). All efficacy endpoints 
will be assessed as the change from Baseline to Week 12. 
Safety will be assessed through adverse events, local skin reactions (LSRs), serum chemistry, 
hematology and urinalysis labora tory testing, ECG testing, physical examination and vital signs. 
Photographs of the face will be take n for all subjects in subset of study sites in order to visually 
assess the appearance of acne vulgari s during the course of the study.  
During clinic visits, subjects will be asked to complete the Acne Patie nt Self-Questionnaire. 
3 STUDY OBJECTIVES  
The objective of this study will be  to assess the efficacy and safety  of Olumacostat Glasaretil Gel 
at a concentration of 5.0%, compared to Olumacos tat Glasaretil Gel, Vehicle when applied twice 
daily for 12 weeks in subj ects with acne vulgaris. 
4 STUDY ENDPOINTS  
Primary Efficacy Endpoints: 
• Mean absolute change in acne lesion counts (inflammatory and non-inflammatory 
lesions) from baseline to Week 12. 
• Proportion of subjects who achieved ≥ 2-grade improvement and a grade of 0 or 1, in the 
investigator global assessment of acne (IGA) from baseline to Week 12. 
Secondary Efficacy Endpoints: 
• Percent change in acne lesi on counts (inflammatory and non-inflammatory lesions) from 
baseline to Week 12. 
• Proportion of subjects who achieved ≥ 2-grade improvement in the investigator global 
assessment of acne (IGA) from baseline to Week 12. 
[ADDRESS_1199983] is ap proximately 17 weeks (up to 35 days screening 
and 12 weeks treatment).  
5.2 Study Population and Number of Subjects 
Approximately 700 subjects, ≥  [ADDRESS_1199984] meet all of the following criter ia to be eligible for study participation: 
1. Signed informed consent and, for subjects under legal adult age, signed assent  
2. Age ≥ 9 years  
3. Willing to comply with the protocol. Subjects under legal adult age will be assessed by [CONTACT_294721]  
4. Male or non-pregnant (negative serum pregnancy test at screening for female subjects of 
child-bearing potential),  non-lactating females 
5. In the case of females of childbearing potenti al), are using an acceptable form of birth 
control ( Section 5.3.4) 
6. In the case of females of childbearing potential, have a negative ur ine pregnancy test at 
Baseline/Day 1  
7. Clinical diagnosis of facial  acne vulgaris defined as: 
• At least 20 inflammatory lesions, and  
• At least 20 non-infla mmatory lesions, and 
• Investigator Global Asse ssment of [ADDRESS_1199985], including topi[INVESTIGATOR_294695].  
5.3.2 Exclusion Criteria 
Subjects meeting any of the following criteria are not eligible fo r study participation: 
1. Previous active treatment in Olumacostat Glasaretil (DRM01B) Gel trials 
[ADDRESS_1199986] at Glasaretil or its excipi[INVESTIGATOR_840] 
4. Any skin condition which may interfere with th e evaluation of safety or, of acne vulgaris 
(e.g., rosacea; seborrheic dermatitis; perioral dermatitis; corticosteroid-induced acne or 
folliculitis) 
5. Excessive facial hair that w ould interfere with diagnosis or assessment of acne vulgaris 
6. Excessive sun exposure that could affect the c linical state of acne, in the opi[INVESTIGATOR_75576], anticipa ted use of tanning booths 
7. Active cystic acne or acne congoblata, acne fulminans, and secondary acne 
8. Two or more active nodulocystic lesions on the face 
9. Screening clinical chemistry, hematology, or urin alysis laboratory valu e, deemed clinically 
significant, by [CONTACT_737] 
10. Abnormal findings on screening ECG, deemed c linically significant by [CONTACT_737]  
11. Subjects who are actively partic ipating in an experimental  therapy study or who have 
received experimental therapy within 30 days or 5 half-lives (whichever  is longer) of the 
Baseline visit 
12. Subjects who are a poor medical risk because  of other systemic diseases or active 
uncontrolled infections, in the opi[INVESTIGATOR_871] 
13. Any other condition which, in th e judgment of the investigat or, would put the subject at 
unacceptable risk for participation in the study 
14. Treatment with over-the-counter topi[INVESTIGATOR_294696], topi[INVESTIGATOR_900]-in flammatory medications, corticosteroids, 
α-hydroxy/glycolic acid on the face w ithin 2 weeks prior to Baseline 
15. Treatment with systemic corticosteroids (use  of intranasal and i nhaled corticosteroids 
allowed for seasonal allergies and asth ma) within [ADDRESS_1199987] emic anti-acne drugs within 4 weeks prior to 
Baseline 
17. Prescription topi[INVESTIGATOR_294697] 4 weeks prior to Baseline (e.g., 
tretinoin, tazarotene, adapalene) 
18. Treatment with a new hormonal therapy or dose change to existing hormonal therapy 
within 12 weeks prior to Baseline (hormonal therapi[INVESTIGATOR_31430], but are not limited to, 
estrogenic and progestational agents  such as birth control pi[INVESTIGATOR_3353]). 
19.  Use of androgen receptor blockers (such as spi[INVESTIGATOR_294698]) within 2 weeks 
prior to Baseline. 
20. Oral retinoid use (e.g., isotretinoin) within 12 months prior to Baseline or vitamin A 
supplements greater than 10,000 units/day within 6 months prior to Baseline 
06 October 2016 Page 16 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
21. Facial procedures (chemical or laser peel, microdermabrasion, etc.) within 8 weeks prior to 
Baseline or if anticipated during the study 
5.3.3 Females – Non-childbearing Potential 
Female subjects of non-childbearing potential are women [ADDRESS_1199988] erile (e.g., total hysterectomy, b ilateral oophorecto my). All other 
female subjects will be considered to be of childbearing potential. 
5.3.4 Females – Childbearing Potential 
Pregnancy hormones may cause acne to flare. To avoid confounding the assessment of efficacy 
pregnancy should be avoided. Acceptable cont raceptive methods for sexually active female 
subjects of childbearing potential  include one of the following: 
• Abstinence 
• Oral/implant/injectable/transdermal contraceptives 
• Intrauterine device 
• Condom with spermicide 
• Diaphragm with spermicide 
• Partner vasectomized or 
• Tubal ligation 
Abstinence or vasectomies are accep table if the female subject ag rees to implement one of the 
other acceptable methods of birth control if her lifestyle/partner changes. Female subjects of 
childbearing potential must use acceptable met hods of contraception starting from the Screening 
Visit and throughout the study.  
[ADDRESS_1199989] at Glasaretil Gel, 5.0% and Olumacostat 
Glasaretil Gel, Vehicle.  
Olumacostat Glasaretil Gel is formulated as an alcohol based gel fo r topi[INVESTIGATOR_59407]. 
Olumacostat Glasaretil Gel, 5.0% contains 50 mg of olumacostat glasaretil per gram of gel, 
ethanol, isopropanol, polyethylen e glycol 400, dimethyl isosorbide and hydroxypropy-cellulose 
and appears as a translucent, colorless to faintly yellow gel.  Olumacostat Glasaretil Gel, Vehicle has the same  appearance and contains the same ingredients 
as Olumacostat Glasaretil Gel, 5.0%, with  the exception of olumacostat glasaretil. 
06 October 2016 Page 17 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
6.2 Packaging, Labeling and Storage 
The Olumacostat Glasaretil Gel, 5.0% and Olum acostat Glasaretil Gel, Vehicle gel will be 
packaged in identical 45g aluminum tubes. E ach tube contains appr oximately 40g of gel.  
Study drug for each subject enrolled will be packaged in a study kit. Each kit will contain 6 tubes 
to allow for 12 weeks of  study drug application.  
Study drug tubes and kits will be labeled with the study number, a unique kit number, contents, 
storage conditions, manufacturer and Sponsor in formation, and precautionary statements and 
expi[INVESTIGATOR_5695], if  applicable.  
Study drug kits are to be stored at room temperature (25°C with allowable excursion to 15-30°C) 
in a secure, locked facility accessible only to au thorized study personnel.  Study drug must not be 
placed in refrigerator or frozen, exposed to heat  or stored at high temperatures. This product is 
flammable. Avoid fire, flame, or smoking during and immediately following application. 
6.3 Treatment Assignment 
Randomization and IWRS 
At the Baseline/Day 1 visit, qualified subjects  will be randomized to treatment using an 
Interactive Web-based Randomization System (IW RS). The IWRS will assign a study drug kit 
number based on a predetermined randomization schedule. The kit number will be recorded in 
the electronic case report form (eCRF). Approxima tely 467 subjects will be randomized to active 
treatment and approximately 233 subjects will be ra ndomized to vehicle treatment for a total of 
approximately 700 subjects. Subjects will be random ized to treatment groups in such a manner to 
balance treatment allocation with in study sites in a 2:[ADDRESS_1199990] will be dispensed 
enough tubes to allow dosing until the next visit. Pa rtially used tubes may be re-dispensed at the 
site’s discretion. 
Subjects are to return all study medication tubes (used and unused ) to the study site. Study tubes 
will be weighed prior to dispensing and upon retur n. Sites are allowed to re-dispense tubes. If 
required, tubes will be re-weighed prior to re-dispe nsing Weights will be recorded in the source 
documents and eCRF.  Each subject is to be instructed  on the importance of re turning study drug at the next study visit. 
If a subject does not return study drug, they will be instructed to return it as soon as possible. The 
site staff will visually inspect the tube to ensu re product usage is consistent with the subject’s 
dosing diary.  
6.[ADDRESS_1199991] dose of the study 
drug will be applied in the clinic for instructi onal purposes. Subjects are to apply the study drug 
twice daily (morning and eveni ng) to a clean dry face.  
Study drug is to be applied topi[INVESTIGATOR_897], to the entire face (forehead, nose, cheeks, and chin) by 
[CONTACT_294722] ½ inch or slightly more th an [ADDRESS_1199992]. Study drug 
accountability records will be reviewed regular ly throughout the study by [CONTACT_1034]/designee. 
Study medication will be returned to the Sponsor, or designee, at the end of the study, following 
final study drug accountability.  
7 CONCOMITANT MEDICATIONS AND PROCEDURES  
All medications (including over-the-counter drugs, vitamins, antacids and skin care products) 
taken during screening and throughout the study w ill be recorded on the eCRF. In addition, to 
ensure that the subject meets the acne treatment and medication exclusion criteria, all acne 
treatment and medications, includ ing, any past isotretinoin, faci al procedures, Vitamin A and 
hormonal therapy use will be recorded on the eCRF.  
Medication entries should be specific to the gene ric name (if a combination drug, then marketed 
product name) and will include the dose, unit, frequency, route of administration, start date, 
discontinuation date, and indica tion. When listing medications indicated for acne, the area 
treated will be collected.  The Investigator should examine the acceptability  of all concomitant procedures, medications, 
topi[INVESTIGATOR_294699]. In order to 
ensure that appropriate concomitant therapy is  administered, subjects will be instructed to 
consult with the Investigator  prior to taking any medicati on (either self-a dministered non-
prescription drugs or prescription ther apy prescribed by [CONTACT_20427]). 
7.1 Permitted Treatments and Procedures 
The use of concomitant medications for medi cal conditions (e.g., hypertension, diabetes, acute 
infections) or treatment of an adverse event is  permitted during this study as long as medications 
are not explicitly prohi bited by [CONTACT_760].  
Non-medicated moisturizers and make-up may be used during study participation, provided 
application occurs after study medication is applied. On st udy visit days, non-medicated 
moisturizers and make-up must be removed prior to each study visit as instructed by [CONTACT_737]. Subjects’ skin care regimen should remain stable/unchanged during study participation.  
Non-medicated moisturizers, soaps, and make-up do not need to be recorded as concomitant 
medications. 
7.2 Prohibited Treatments and Procedures 
Subjects should not undergo any elective medical pr ocedure without prior c onsultation with the 
Investigator. Elective out-patient procedures (e.g., minor outpatient  surgery) that might require 
[ADDRESS_1199993]’s best interest. 
The following medications and treatments  are prohibited during the study:  
• Over-the-counter topi[INVESTIGATOR_294701], 
topi[INVESTIGATOR_900]-inflammatory medications, corticosteroids, α-hydroxy/glycolic acid  
• Systemically absorbed anti-acne drugs 
• Systemic corticosteroids (use of intranasal and inhaled cortic osteroids allowed for 
seasonal allergies and asthma) 
• Systemic antibiotics (except in the case of  acute medical need to treat infections) 
• Prescription topi[INVESTIGATOR_294702](e.g., tretinoin, tazarotene, adapalene) 
• New hormonal therapy or dose change to ex isting hormonal therapy. Hormonal therapi[INVESTIGATOR_182019], but are not limited to, es trogenic and progestational ag ents such as birth control 
pi[INVESTIGATOR_3353].  
• Use of androgen receptor blockers (s uch as spi[INVESTIGATOR_294698]) 
• Oral retinoid use (e.g., isotretinoin) or  vitamin A supplements greater than 
10,000 units/day  
• Facial procedures (chemical or la ser peel, microdermabrasion, etc.) 
• Sun exposure which in the opi[INVESTIGATOR_294703] e course of acne or 
any tanning booth use 
[ADDRESS_1199994] evaluation at  each study visit are outlined below and in the 
study Schedule of Visits and Procedures (see Appendix 1 ). The timing of each study day is 
relative to the day of initial dosing (Baseline/Day 1). Visit wi ndows are provided to allow study 
sites some flexibility in maintaining the study vi sit schedule for participating subjects. Out of 
window visits may be unavoidable in certain ci rcumstances. Out of window visits are not 
considered deviations to the protocol. 
8.1 Screening (Day -35 to -1) 
The screening evaluation period ma y take up to [ADDRESS_1199995] be assigned a new screening number. Screen failure information 
will be recorded in the eCRF. Screening proced ures, excluding lab evaluations, may be done any 
time during the screening period (prior to dosi ng on Day 1) and after the subject has given 
informed consent.  
06 October 2016 Page 21 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
• Obtain written informed consent/assent. For subjects under legal a dult age, both parents 
or legal representatives may be required to sign informed consent as applicable. 
• Collect demographic information 
• Complete medical history 
• Query subject for concomitant medication use 
• Perform a complete physical examination 
• Record height and weight 
• Measure vital signs 
• Assess Inclusion/Exclusion criteria 
• Collect a 12 lead ECG 
• Draw blood samples for laboratory tests a nd urine for urinalysis. Include serum 
pregnancy test for women of childbearing potential 
• Determine concomitant medication washout duration 
• Schedule next visit 
8.2 Baseline Visit/ Day [ADDRESS_1199996] dose of study drug 
• Collect concomitant medication information 
• Conduct a symptom-directed physical exam – update medical history if appropriate 
• Measure vital signs 
• Conduct urine pregnancy test for women of childbearing potential 
• Conduct Investigator Global Assessment (IGA) 
• Collect acne lesion counts 
• Collect Acne Patient Self- Questionnaire 
• Evaluate face for pre-treatment local skin reactions (LSRs) 
• Collect photographs (selected sites) 
• Confirm subject eligibility (Inclusion/Exclusion criteria) and randomization to treatment 
• Instruct subject on study medication application and diary completion 
• Weigh tubes and dispense study drug and diar y. Observe subject administering first dose 
• Schedule all subs equent visits 
06 October 2016 Page 22 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
8.3 Week 1 (+/-2 days) 
• Collect concomitant medication information 
• Conduct a symptom-directed physical exam 
• Measure vital signs 
• Review and record AEs 
• Assess LSRs 
• Review compliance/weigh tubes and dispense drug and diary 
• Schedule Week [ADDRESS_1199997] (+/-2 days) 
• Call subject to review AEs and concomitant medications 
8.5 Week 4 (+/-4 days) 
• Collect concomitant medication information 
• Conduct a symptom-directed physical exam 
• Collect urine pregnancy for wo men of childbearing potential 
• Measure vital signs 
• Review and record AEs 
• Conduct IGA 
• Collect acne lesion counts 
• Collect Acne Patient Self-Questionnaire 
• Assess LSRs 
• Collect photographs (selected sites) 
• Review compliance/weigh tubes a nd dispense drug and diary  
8.6 Week 8 (+/-4 days) 
• Collect concomitant medication information 
• Conduct a symptom-directed physical exam 
• Collect urine pregnancy for wo men of childbearing potential 
• Measure vital signs 
• Review and record AEs 
• Conduct IGA 
06 October 2016 Page 23 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
• Collect acne lesion counts 
• Collect Acne Patient Self-Questionnaire 
• Assess LSRs 
• Collect photographs (selected sites) 
• Review compliance/weigh tubes and dispense drug and diary 
8.7 Week 12 (+/-4 days) Study Exit or Early Termination Visit 
• Collect concomitant medication information 
• Measure vital signs 
• Review and record AEs 
• Conduct a complete physical exam 
• Measure weight  
• Collect a 12-lead ECG 
• Draw blood samples for laboratory tests. In clude serum pregnancy test for women of 
childbearing potential. 
• Conduct Investigator Global Assessment 
• Conduct acne lesion counts 
• Collect Acne Patient Self-Questionnaire 
• Assess LSRs 
• Collect photographs (selected sites) 
• Review compliance/weigh tubes and co llect all study medi cation and diary 
8.[ADDRESS_1199998] procedures may be needed for 
younger subjects qualifying for study participation. 
06 October 2016 Page 24 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
9.1 Screening Assessments 
9.1.1 Demographics  
At the screening visit, demographic information including age, gender, race, Fitzpatrick Skin 
Type ( Table 1 ) and ethnicity will be collected and r ecorded on the eCRF for each subject.  
Table 1: Fitzpatrick Skin Type 
Fitzpatrick Skin Type Definition 
I Burns easily, rarely tans 
II Burns easily, tans minimally 
III Burns moderately, tans gradually 
IV Burns minimally, tans well 
V Rarely burns, tans profusely 
VI Never burns, deeply pi[INVESTIGATOR_49194] 
9.1.[ADDRESS_1199999] or coexisting medical conditions or surgeries. The medical history will be updated prior to treatment on Baseline/Day 1, sh ould new findings emerge after the screening 
visit. Findings will be recorded in the eCRF. 
9.1.[ADDRESS_1200000]’s acne vulgaris will be collected as part of the screening assessment 
and include the date of onset of acne, anatomical areas affected at baseline, and past treatments 
used for acne vulgaris. Information will be recorded in the eCRF.  9.2 Assessment of Efficacy 
9.2.1 Investigator Global Assessment 
The IGA is a static assessment of acne severity ( Table 2 ) on the face only and will be conducted 
for each subject by [CONTACT_294725] c ounts or conducting the 
LSR assessment. Where possible, the same efficacy assessor should assess acne severity on the 
same subject at all visits. Individuals performing the IGA will be trained and certified prior to conducting any assessments on the study. IGA grad es will be entered into the eCRF.  
06 October 2016 Page 25 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
Table 2: Investigator Global Assessment 
Investigator Global Assessment 
Grade  Description  
0 Clear; normal, clear skin with no evidence of acne vulgaris 
[ADDRESS_1200001] clear; Rare non-inflammatory lesions presen t, with rare non-inflamed papules (papules 
must be resolving and may be hyperpi[INVESTIGATOR_49194], though not pi[INVESTIGATOR_8745]-red) 
2 Mild; some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules 
only; no nodulocystic lesions) 
3 Moderate; non-inflammatory lesions predominate,  with multiple inflammatory lesions evident: 
several to many comedones and papules/pustules, and there may or may not be one small nodulocystic lesions 
4 Severe; Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be a few nodulocystic lesions 
9.2.2 Acne Lesion Count 
The investigator/designee will pe rform a count of inflammatory lesions (papules, pustules and 
nodules) and non-inflammatory lesions (open and closed comedones) and will be conducted after  
the IGA assessment is completed. Lesion counts ar e confined to the face (including forehead, 
nose, cheeks, and chin) and exclude submental lesions. Where possible, the same efficacy 
assessor should perform all lesion count asse ssments on the same subject at all visits.  
Individuals performing the acne lesion counts will be trained a nd certified prior to conducting 
any assessments on the study. Lesion count s will be entered into the eCRF. 
9.[ADDRESS_1200002] photos to the Sponsor 
during the course  of the study. 
06 October 2016 Page 26 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
9.3.2 Acne Patient Self-Questionnaire 
Subjects will be asked to complete Acne Patien t Self-Questionnaire. The questionnaire is paper-
based and will be completed by [CONTACT_294726] (see Appendix 2 ). Subject responses 
will be entered in the eCRF by [CONTACT_3433] e study site and the completed questionnaires kept as part of the 
subject’s source document. Study site staff must re view all forms to ensure complete responses 
prior to a subject l eaving the study site.  
9.[ADDRESS_1200003]’s weight will be reco rded with the end of study physical exam. A symptom-directed 
physical exam may be performed at subsequent visits as needed. Following baseline, any new 
findings or findings that have worsened in severity should also be recorded as an AE.  
Physical exam findings will be recorded in the eCRF. 
9.4.2 Vital Signs 
Vital signs, including body temperature, respi[INVESTIGATOR_697] (breath per minute), pulse (beats per minute), and blood pressure (mmHg), will be obtain ed with the subject in the seated position, 
after sitting for at least [ADDRESS_1200004] eligibility. 
The medical monitor may be consulted if  needed for interpretation of ECGs. 
All study sites will be supplied with standardized , validated digital 12-lead ECG (12-lead at 
25 mm/sec reporting rhythm, ventricu lar rate, the RR interval, the PR interval, QRS duration, QT 
and QTcF intervals) equipmen t capable of recording, stor ing, and printing producing high 
resolution 12-lead ECG data by [CONTACT_2237]. Study sites will be trained on the use of 
the equipment prior to study start.  
Machine-read ECG recordings will be collected a nd analyzed centrally. Data will be transferred 
electronically to the database. 
06 October 2016 Page 27 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
9.4.4 Laboratory Evaluations  
Laboratory tests will be collected to evaluate safety in all study subjects and analyzed using a 
central laboratory. Labs will be collected per the Schedule of Visits and Procedures (see 
Appendix 1) or more frequently as clinically indicat ed. Laboratory samples are to be shipped on 
the same day as collected. No more than 4 mL/kg total will be collected over an 8 week period in 
subjects under legal adult age. Labor atory tests are described below.  
Hematology: hematocrit, hemoglobin, red blood cell (RBC) count, white blood cell count and differential (%), mean cor puscular hemoglobin (MCH), m ean corpuscular hemoglobin 
concentration (MCHC), mean corpuscular volume, platelet count, absolute  neutrophils, absolute 
lymphocytes, absolute monocytes, absolute  eosinophils, and absolute basophils. RBC 
morphology should be performed if indicated. 
Chemistry:  sodium, potassium, chloride, calciu m, phosphorus, bicarbonate, uric acid, blood urea 
nitrogen (BUN), creatinine, total protein, albumi n, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase, bilirubin (total and direct), and glucose (fasting or 
non fasting). Serum pregnancy testing will be performed at th e screening and Week 12 (study exit) or Early 
Termination visits. Urine pregnancy test ing (beta human chorionic gonadotropin [ β-hCG]) will 
be performed at Baseline/Day 1, and the Weeks [ADDRESS_1200005]-
menopausal/sterile.  
Urinalysis:  pH, specific gravity, protein, glucose, ketones, bili rubin, blood, nitrite, urobilinogen, 
leukocyte esterase. A microscopic examination of ur ine will be performed if  clinically indicated 
(e.g. a positive dipstick for protein, blood, leucocyte esterase) in the opi[INVESTIGATOR_294704] . Any new or worsened 
clinically significant laboratory result is to be recorded as  an AE after study drug dosing. 
Screening laboratory values must be reviewed by  [CONTACT_294727]. 
Subjects will be screen failed for clinically si gnificant laboratory valu es. Screening laboratory 
tests may be repeated one time in order to confirm out of range results clinical significance at the 
discretion of the investigator.  The central laboratory must be used for any labo ratory testing required for a subject during study 
participation, including laboratory testing needed for unscheduled visits. If an immediate result is 
required to adequately care for a subject, a duplicate sample may be submitted to a local lab. Clinically significant laboratory results must be recorded as an AE, preferably as a diagnosis rather than individual test resu lts. Any subject who has a clinical ly significant laboratory test 
result will be evaluated by [CONTACT_737], and will be treated and/or followed up until the value 
returns to clinically acceptable level,  in the opi[INVESTIGATOR_871]. 
9.4.5  Local Skin Reactions (LSRs) 
All subjects will be assessed for LSRs, on the fa ce, at each visit. LSRs include burning/stinging, 
pruritus, erythema, dryness and peeling. Each LSR will be scored as 0 (None), 1 (Mild), 2 (Moderate) or 3 (Severe). LSRs observed on a vis it day will not be recorded as adverse events 
06 October 2016 Page 28 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
unless scored as 3 (Severe). Local skin reactio ns experienced by [CONTACT_941] s ubject in between study 
visits are to be recorded as an AE.  
Burning/stinging and pruritus wi ll be assessed by [CONTACT_423] ( Table 3 ) and erythema, dryness 
and peeling will be assessed by [CONTACT_737]/designee ( Table 4 ). Subjects will be read the 
definition of each subject-assessed LSR and aske d to select the appropriate definition. The 
corresponding score will be assigned by [CONTACT_294728]. 
Table 3: Subject Assessed Local Skin Reactions 
Score  Grade  Burning/Stinging  Pruritus  
0 None No stinging/burning No pruritus 
1 Mild Slightly warm, tingling sensation; not 
really bothersome Occasional, slight itching/scratching 
2 Moderate Definite warm; tingling/stinging sensation that is somewhat bothersome Intermittent itching/scratching which does not disturb sleep 
3 Severe Hot, tingling/stinging sensation that has caused definite discomfort Bothersome itching/scratching which disturbs sleep 
Table 4: Investigator Assessed Local Skin Reactions 
Score Grade Erythema Dryness Peeling 
0 None None None None 
1 Mild Slight erythema: very light-pi[INVESTIGATOR_294705] 
2 Moderate Dull red, clearly distinguishable Easily noted dryness and flakes but no fissure formation Moderate diffuse peeling 
3 Severe Deep/dark red Easily noted dryness with flakes and fissure formation Moderate to prominent, dense peeling 
9.4.6 Adverse Events 
An adverse event (AE) is define d as any untoward medical occurren ce associated with the use of 
a study drug in humans, whether or not consider ed drug related. An AE can, therefore, be any 
unfavorable and unintended sign (i ncluding an abnormal laboratory finding), symptom or disease 
temporally associated with the use of the study dr ug, whether or not related to the investigational 
product.  
AEs will be monitored throughout the study. Subj ects will be instruct ed to inform the 
Investigator and/or study staff of  any AEs. At each visit, subjects  will be asked about AEs in a 
non-specific manner using open-ended questions so as not to bias the response (e.g., How have 
you been since the last visit?).  Specific inquiry regarding reported AEs will be conducted when 
applicable. All AEs will be documented and recorded in the subject’s eCRF. 
Any subject who has an AE (seri ous or non-serious) or clinically significant abnormal laboratory 
test value will be evaluated by [CONTACT_737], and will be treated and/or followed up until the 
symptoms or values return to normal or to clinically acceptable le vels, as judged by [CONTACT_941] 
06 October 2016 Page 29 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
Investigator. A physician, either at clinical si te, or at a nearby [CONTACT_2360][INVESTIGATOR_9487], will 
administer treatment for any serious adverse ev ents (SAEs), if necessary. When appropriate, 
medical tests and examinations will be perf ormed to document resolution of event(s). 
[IP_ADDRESS] Reporting 
Only AEs that occur during or following study tr eatment with the study dr ug will be reported in 
the AE section of the eCRF. Events recorded prior to study treatment with the drug will be 
reported in the Medical History se ction of the eCRF as appropria te. All AEs occurring during the 
course of the study will be individually recorded in the eCRF. A condition that is present prior to 
administration of study drug and that worsens after administration of study drug should be 
reported as an AE. Information regarding the onset, duration, severity, action taken, outcome, 
and relationship to study drug will be recorded.  
New or worsening abnormal laboratory values and/ or vital signs are to be  recorded as AEs if 
they are considered to be of clinical significance  by [CONTACT_294729] 9.4.7. 
Unless a diagnosis is available, signs and symptoms must be re ported as individual AEs in the 
eCRF; a diagnosis is preferred. The severity of an AE will be de signated as mild, moderate or seve re. The term “severe” is used 
to describe the intensity of an adverse event;  the event itself, however , may be of relatively 
minor clinical significan ce (e.g. ‘severe’ upper resp iratory infection). Severity is not the same as 
“serious”. Seriousness of AEs is based on the outcome/action of an AE. (See Section 9.4.7.) 
The relationship of the AE to the study treatment should be determined by [CONTACT_143228]: Not related :  An AE is defined as “not related” if th e AE is not judged to be associated with the 
study drug and is attribut able to another cause 
Related:   An AE is defined as “related” where a causal relationship between the event and the 
study drug is a reasonable possibility (possibl y or probably related) . A reasonable causal 
relationship is meant to convey that there are facts (e.g., evidence such as dechallenge/ 
rechallenge) or other clinical arguments to suggest a causal relationship between the AE and 
study treatment.  
9.4.7 Serious Adverse Events 
A Serious Adverse Event (SAE) is defined as an y untoward medical occurrence that, at any dose, 
• Results in death 
• Is imm ediately life-threatening (i.e., in the opi[INVESTIGATOR_273554], the AE places the 
subject at immediate risk of death; it does not include a reactio n that, had it occurred in a 
more severe form, might have caused death) 
• Requires inpatient hospi[INVESTIGATOR_294706] 
06 October 2016 Page 30 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect 
• Is an important medical event that may not be immediately life-threatening, result in 
death, or require hospi[INVESTIGATOR_18543], but may be considered an SAE when, based upon 
appropriate medical judgment , it jeopardizes the subject or may require medical or 
surgical intervention to prevent one of the outcomes listed above 
As soon as the Investigator becomes aware of an AE that meets the criteria for an SAE, the SAE 
should be documented to the extent that inform ation is available. A report must be submitted by 
[CONTACT_294730] [ADDRESS_1200006] be reported to the Spons or immediately (within 
24 hours of the Investigator’s  knowledge of the event).  
SAEs will be recorded from the time of informed  consent/assent, through to end of the study. If, 
in the opi[INVESTIGATOR_273554], an SAE occurring outside the specified time window, (i.e., 
following subject completion or terminations of th e study) is deemed to be drug-related, then the 
event should be reported w ith [ADDRESS_1200007] death, any pos t-mortem findings/reports will be requested. 
[IP_ADDRESS] Reporting of Serious Adverse Events 
All SAEs, as defined by [CONTACT_29967], must be  reported to the Sponsor or designee using the 
SAE form provided, within [ADDRESS_1200008] nu mber, event description, 
SAE term(s), reason why the event is considered to be serious (i.e., the se riousness criteria), and 
PI’s assessment of the relationship of the event to study drug. Additional SAE information 
including medications or othe r therapeutic measures used to treat the event, and the 
outcome/resolution of the event should also be recorded on the SAE form. 
In all cases, the Investigator s hould continue to monitor the c linical situation and report all 
material facts relating to the progression or outcome of the SA E. The Investigator may be 
required to provide supplementary information as  requested by [CONTACT_4885]. 
When reporting SAEs, the following additional points should be considered: 
• When the diagnosis of an SAE is known or suspected, the Investig ator should report the 
diagnosis or syndrome as the primary SAE term, rather than as signs or symptoms; signs, 
symptoms and tests that support th e diagnosis should be provided  
• Death should not be reported as an SAE, but as an outcome of a specific SAE, unless the 
event preceding the death is unknown. If an au topsy was performed, the autopsy report 
should be provided; 
[ADDRESS_1200009] hospi[INVESTIGATOR_294707], some hospi[INVESTIGATOR_294708], as follows:  
• Hospi[INVESTIGATOR_294709] a pre-
existing condition that has not worsened after administration of study drug (e.g., a 
previously scheduled ventral hernia repair). SAEs must, however, be reported for any 
surgical or procedural complication result ing in prolongation of the hospi[INVESTIGATOR_059]; 
• Events that result in hospi[INVESTIGATOR_294710] 24 hours and that do 
not require a therapeutic in tervention/treatment (e.g., an emergency room visit for 
hematuria that results in a diagnosis of cystitis an d discharge to home on oral antibiotics). 
The Sponsor will process and evaluate all SAEs as soon as the reports are received. For each 
SAE received, the Sponsor will make a determina tion as to whether the criteria for expedited 
reporting to relevant regulatory authorities have been met.  
The Sponsor will assess the expectedness of each SAE to the study treatment. The current 
Investigator’s Brochure will be used as the reference document to assessed expectedness of the event to study drug. 
9.4.[ADDRESS_1200010] experience intole rable treatment-related adverse 
events (e.g., pruritis) on study. In cases where th e Investigator feels a dose interruption is 
warranted, the subject should be instructed to in terrupt study drug applica tion to allow symptoms 
to resolve. Subjects should be in structed to return to the twice daily application regimen within [ADDRESS_1200011] be obtained. Pregnancy is not 
itself an AE or SAE; however, maternal/fetal comp lications or abnormalities will be recorded as 
AEs or SAEs, as appropriate. The Investigator must complete a study-specific pregnancy form 
upon confirmation of a pregnancy. Pregnancy reporting forms will be provided to the study site. 
06 October 2016 Page 32 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
10 STUDY DISCONTINUATIONS  
10.1 Discontinuation of the Study 
The Sponsor has the right to terminate or to stop the study at any time. Should this be necessary, 
both the Sponsor and the Investigator will ensu re that proper study discontinuation procedures 
are completed. The entire study will be stopped if: 
• Evidence has emerged that, in the collective opi [INVESTIGATOR_294711], makes the 
continuation of the study unnecessary or unethical 
• The stated objectives of the study are achieved 
• The Sponsor discontinues the development of the study drug 
Regardless of the reason for w ithdrawal, all data available fo r the subject at the time of 
discontinuation of follow-up must be recorded in the eCRF. All reasons for discontinuation of 
treatment must be documented. 
10.[ADDRESS_1200012] in  the study; however, a 
subject may voluntarily withdraw from study participation at any time. If the subject withdraws 
consent and discontinues from the study, the I nvestigator will attempt to schedule an Early 
Termination visit as soon as possible, determ ine the reason for discon tinuation, and record the 
reason in the subject’s study records and in the eCRF.  
If at any time during the study, the In vestigator determines that it is not in the best interest of the 
subject to continue, the subject  will be discontinued from part icipation. The Investigator can 
discontinue a subject at any time if medically necessary. The Investigator may discontinue a 
subject’s participation if  the subject has failed to follow study procedures or to keep follow-up 
appointments. Appropriate documentation in the s ubject’s study record an d eCRF regarding the 
reason for discontinuation must be completed. 
All subjects who fail to return to the study site for the required follow-up visits will be contact[CONTACT_294731](s) why the subject failed to return for the necessary visit or 
elected to discontinue from the study. If a subject is unreachable by [CONTACT_34675] a minimum 
of two documented attempts (one attempt on two different days), a registered letter will be sent requesting that subject contact [CONTACT_3433] e site regarding study follow-up.  
Subjects will be discontinued early from th e study if any of the following occur: 
• Withdrawal of informed consent (subject ’s decision to withdraw for any reason) 
• Any clinical adverse event, la boratory abnormality, or inter- current illness which, in the 
opi[INVESTIGATOR_689], indi cates that continued treatment and/or participation in the 
study is not in the best interest of the subject 
• Death 
06 October 2016 Page 33 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
• Serious protocol violation, including persistent noncom pliance or subject requiring 
medication or procedures prohibited by [CONTACT_138773], to allow subj ects to receive the 
appropriate medical attention.  
• Discontinuation of the study by [CONTACT_1034] 
10.3 Study Drug Discontinuation 
For subjects who decide to prematurely discontinue study drug treatment, all reasonable efforts 
should be made to obtain all protocol-specified safety assessments and end of study procedures.  
The Investigator should stop study drug treatment in the following instances: 
• Inter-current illness that would, in the judgment of the Investigator, affect assessments of 
clinical status to a significant degree.  
• Any clinical adverse event whic h is clinically significant a nd is deemed persistent and 
probably or definitely rela ted to study drug in the j udgment of the Investigator. 
• Unacceptable toxicity 
11 STATISTICAL CONSIDERATIONS  
11.1 General Statistical Methodology 
All statistical processing will be performed us ing SAS® unless otherwise stated. No interim 
analyses are planned. Except where noted, all st atistical tests will be two-sided and will be 
performed at the 0.05 le vel of significance.  
Descriptive statistics will be us ed to provide an overview of th e efficacy and safety results. For 
categorical parameters, the number and percen tage of subjects in each category will be 
presented. For continuous parameters , descriptive statistics will in clude n (number of subjects), 
mean, standard deviation (SD), median, mini mum and maximum. Appr opriate inferential 
statistics will be used for the primary, s econdary, and exploratory efficacy variables. 
The primary method of handling missing efficacy data will be the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation.  
Demographic data will be summarized by [CONTACT_2070]. Subjects’ 
baseline characteristics related to efficacy anal yses will be compared between treatment groups 
to evaluate baseline balance between the treatment arms. 
The number of subjects in each analysis set will be summarized. Reasons for study withdrawal 
during the blinded study will be summarized usi ng frequencies and percentages by [CONTACT_6490]. 
The primary method of dichotomizing the IGA score will be to consider a subject a “success” if 
the IGA at a post-baseline visit is 0 or 1 and 2 or  more grades lower than  at baseline; otherwise 
the subject will be considered a treatment “failure”. 
06 October 2016 Page 34 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
A statistical analysis plan (SAP), describing all st atistical analyses will be provided as a separate 
document. The SAP will be finalized prio r to unblinding of the study treatments.  
11.2 Populations Analyzed 
Listings and summaries will be pr ovided for all randomized subjects. 
Approximately 700 subjects with acne vulgaris on th e face will be randomized, in a 2: 1 fashion, 
to Olumacostat Glasaretil Gel,  5.0% BID, or Olumacostat Glas aretil Gel, Vehicle. Efficacy 
analyses will be performed usi ng the intent-to-treat (ITT) popul ation and the per-protocol (PP) 
population. Safety analyses will be performed using the safety population. 
All subjects who are randomized and dispen sed study drug will be included in the ITT 
population.  All subjects who are randomized, receive at le ast one confirmed dose of study drug and have at 
least one post-baseline safety assessment will be included in the safety population. The PP population will include all subjects in th e safety population who complete the Week 12 
evaluation without any significant pr otocol violations (i.e., any subject or investigator activity 
that could have possibly interfered with the th erapeutic administration of the treatment or the 
precise evaluation of treatment efficacy). The PP  population will include subjects in the safety 
population who do not meet any of the following criteria: 
• Violated the inclusi on/exclusion criteria; 
• Have taken any interfering concomitant medications; 
• Did not attend the Week 12 visit; 
• Have missed both the Week 4 and Week 8 study visits; 
• Have not been compliant with the dosi ng regimen (i.e. subjects must apply 80 −120% of 
the expected applications of study medi cation during particip ation in the study); 
• Out of visit window at the Week 12 visit by ±5 days; 
Subjects that discontinue from the study due to an adverse event relate d to study treatment or 
documented lack of treatment effect will be incl uded in the PP population. Prior to breaking the 
blind, other additional criteria may be added to the list to accommodate for unforeseen events 
that occurred during the conduct of  the trial that result in note worthy study protoc ol violations. 
11.[ADDRESS_1200013] will be 
included in the model; otherwise it will be removed. 
A skewness test, based on the methods presented by J.H. Zar (1984) [14], will be applied to the 
residuals resulting from an ANCOVA. A two-sided p-value for the skewness test significant at 
0.01 will imply the use of the non-parametric method. If a parametric analysis is indicated, the 
results of the parametric analysis will be  considered the primar y analysis. Should a non-
parametric analysis be indicated, the absolute  or percent changes in inflammatory and non-
inflammatory lesions will be rank transforme d prior to submitting them to the ANCOVA. 
Results of the rank-transformed an alyses then will be considered  the primary an alysis; however, 
results of the non-ranked transformed analyses will also be presented. 
The proportion of subjects who are dichotomized to success at Week [ADDRESS_1200014] ratified by [CONTACT_85229].  
11.4 Secondary Efficacy 
The percent change from baseline to Week 12 in inflammatory and non-inflammatory lesion 
counts will be analyzed usi ng the same ANCOVA method desc ribed for the primary endpoint. 
The proportion of subjects who are dichotomized  to success (minimum 2-grade improvement 
from baseline) at Week [ADDRESS_1200015] for a step is not significant. All 
subsequent tests for the remaining steps will be co nsidered not significant. The order of testing is 
percent change in inflammatory lesion count from baseline to Week 12, percent change in non-
inflammatory lesion count from baseline to Week 12, and the proportion of subjects who are 
dichotomized to success (minimum 2-grade improvement from baseline). 
11.[ADDRESS_1200016]  in characterizing the therapeutic efficacy of the 
active formulation and dosage regimen. No adju stments will be made for multiple comparisons 
for the sportive efficacy analyses. 
Descriptive statistics will be presented for the following para meters by [CONTACT_85216]: 
• Frequency and percent distribut ions of the IGA Score at Baseline and Weeks 4, 8, and 12. 
• Frequency and percent distri butions of the dichotomized  IGA Score at Baseline and 
Weeks 4, 8, and 12. 
06 October 2016 Page 36 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
• Descriptive statistics including mean, me dian, standard deviation, minimum, and 
maximum will be used to summarize inflammatory and non-inflammatory lesion counts 
at Baseline and Weeks 4, 8, and 12.  
• Descriptive statistics including mean, me dian, standard deviation, minimum, and 
maximum will be used to summarize the absolute and percent change in inflammatory and non-inflammatory lesion counts at Weeks 4, 8, and 12. 
• Descriptive statistics including mean, me dian, standard deviation, minimum, and 
maximum will be used to summarize the Acne Patient Self-Questionnaire assessments at Weeks 4, 8, and 12. 
Means, standard deviations and frequency count s (rounded to the nearest whole number) will be 
computed from the multiply imputed MCMC data for the variable. 
11.6 Pooling Analysis  
The clinical study will be conducted under a common protocol for each investigational site with 
the intention of pooling the data for analysis. Ever y effort will be made to promote consistency 
in study execution at each investigational site. The study is intended to be conducted in a manner 
such that a minimum of 5 subjects will be enrolled  in each treatment arm for any investigator. In 
the event that there are too few subjects in a treatment arm for an investigator, then this 
investigator’s data will be combined to achieve  the desired sample size minimum per arm. The 
combining of investigator’s data will be accomplished by [CONTACT_294732]. If there is a further 
need to combine data, then the data of the inve stigator with the second smallest enrollment will 
be combined with the investigat or’s data which had the second  largest enrollment, and so on. 
This process will continue for all investigator s who did not have a minimum of [ADDRESS_1200017] insufficient subjects 
per treatment arm will result in redefining the groups of investigators for the purposes of 
statistical analyses. These combined groups will be referred to as “analysis centers” in the 
statistical analyses based on ANCOVA and stratified logistic testing.  
Prior to investigating the treatment effect within the analysis centers, the magnitude of the site 
mail effect will be investigated to determine if th e main site-to-site vari ability is such that it 
could mask the analysis center effects. Thus , if computationally po ssible, a one-way ANCOVA 
(for lesion count variables) or a logistic regression analysis (for di chotomized IGA) with a factor 
of site will be conducted prior to pooling. If th e data structure interferes with the logistic 
regression, a descriptive analysis of the site effect will be undertaken. Conclusions appropriate to 
the findings of this step will be presented. 
The consistency of treatment response will be inve stigated across the analysis centers subsequent 
to combining the data as described above. Statisti cal tests will be conducted to identify if there 
are extreme analysis centers that could affect the interpretation of common statistical and clinical 
conclusions. An analysis center by [CONTACT_294733] 0.10. Change 
from baseline in inflammatory lesions and non-inflammatory lesions will be analyzed with an 
ANCOVA (unranked or ranke d) with factors of treatment, an alysis center, and treatment by 
[ADDRESS_1200018] 
a significant ANCOVA or logistic regression interaction term . In the event that the ANCOVA or 
logistic regression intera ction (referred to henceforth as the “appropriate test”)  p-value is less 
than or equal to 0.10, a sensitivity analysis th at excludes analysis cen ters with the extreme 
efficacy result will be performed to determine the robustness of the treatment effect. On the other 
hand, if the outcome of the appropr iate test has a p-value greater than 0.10, then the conclusions 
from the pooled data will be considered to be free of the impact of extreme analysis centers. 
The first step in conducting a sensitivity analysis is to identify the extreme analysis center or 
centers that contribute to the st atistical significance of  the appropriate test . The process involves 
submitting subsets of analysis centers to the appr opriate test and observing the appropriate test 
p-value for the subset. Subsets with p-values greater than 0.[ADDRESS_1200019]-hoc aspects of the process will be given when the results are interpreted. Conclusions will be presented by [CONTACT_85220]. 
11.7 Missing Efficacy Data Imputations 
Lesion Count Variable Missing Data Imputation 
Missing 12 week data will be estimated by [CONTACT_85221]. 
Missing lesion count data will be derived for th e analysis using the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation which does not rely on the assumption of data missing at random. Additionally, the pattern of  missing observations in each treatment group 
[ADDRESS_1200020] phases with these principal 
tasks: 
1. Calculated the number of missing values to be estimated by [CONTACT_85222] (nmiss) for 12-week 
value. 
2. Create a data set of subjects, one for each tr eatment group, with observed values and those 
needing estimation by [CONTACT_85222]. The missing lesion count values in each data set will be 
filled in using the MCMC method ‘5 x nmiss’ times to generate ‘5 x nmiss’ data sets. The resulting data sets for each treatment arm will be combined into one complete data set for each imputation. 
Syntax: 
proc mi data=datain out=dataout s eed=&seed. Nimpute=5xnmiss <options>; 
  where trtpn=(1, or 2);   mcmc chain=multiple;   var baseline week4 week8 week12; run; 
3. For each complete data set, the absolute change in lesion counts for baseline minus the 
12-week value will be computed. Each complete data set will be analyzed as specified for 
the particular analysis. 
4. The results from these analyses will be combined into a single inference using SAS PROC MIANALYZE. 
A total of [ADDRESS_1200021] been pre-specified by [CONTACT_2329] a random number generator: 
• Inflammatory Lesion Counts; Olumaco stat Glasaretil Gel: Seed= 195361148  
• Inflammatory Lesion Counts; Olumacostat  Glasaretil Gel Vehicle: Seed= [PHONE_6133]  
• Non-Inflammatory Lesion Counts; Olum acostat Glasaretil Gel: Seed= 325230329  
• Non-Inflammatory Lesion Counts; Olum acostat Glasaretil Gel: Seed= 936128187  
IGA Missing Data Imputation 
A similar procedure will be used for the anal yses based on proportion of IGA successes wherein 
the ANCOVA analysis is replaced with a logi stic regression analysis. Specifically, missing 
12-week IGA values from which the dichotomized  IGA is derived will be estimated by (MCMC) 
which does not rely on the assumption of data missing at random. Additionally, the pattern of 
missing observations in each treatment group cannot influence the missing value estimation in the other because the imputation is being conducted independently for each treatment group. 
06 October 2016 Page 39 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
The missing 12 week IGA values will be derive d for the analysis using the method of Markov 
Chain Monte Carlo (MCMC) multiple imputation. Multiple imputation and subsequent analysis 
will involve 4 principal tasks: 
1. Calculate the number of missing values to be estimated by [CONTACT_85222] (nmiss) for 12 week 
value. 
2. Create a data set, one for each treatment group, of subjects with observed values and those 
needing estimation by [CONTACT_85222]. The missing IGA valu es in each data set will be filled in 
using the MCMC method ‘5 x nmiss’ times to generate ‘5 x nmiss’ data sets. The resulting data sets for each treatment arm will be combined into one complete data set by [CONTACT_47915]. 
Syntax: 
proc mi data=datain out=dataout s eed=&seed. Nimpute=5xnmiss <options>; 
  where trtpn=(TRT);   /* Note TR T = [1, 2]; depending on treatment group */ 
;   mcmc chain=multiple;   var baseline week4 week8 week12; run; 
3. For each complete data set, the dichotomous su ccess rate (clear or almost clear with a 
2-point change from baseline) will be com puted. The 12-week estimated global values will 
be rounded to the nearest integer value prior to evaluating the success rate. Each complete 
data set will be analyzed w ith a logistic regression with factors of treatment group and 
analysis center. 
4. The results from these analyses will be combined into a single inference using SAS PROC 
MIANALYZE. 
A total of [ADDRESS_1200022] been pre-specifie d by [CONTACT_2329] a random number generator: 
• IGA; Olumacostat Glasaretil Gel: Seed= 322979853  
• IGA; Olumacostat Glasaret il Gel Vehicle: Seed= [PHONE_6134]  
11.[ADDRESS_1200023] sensitivity analysis for absolute cha nge in lesion count use a repeated measures 
ANCOVA, with treatment, analysis center, and visit (ie, Week 4, W eek 8) as independent factors 
and a covariate of baseline lesion count. In this an alysis, data from all post-baseline visits will be 
included with no imputation for missing data. 
The second sensitivity analysis will use the m odel based multiple imputation method to impute 
missing data for the absolute change in lesion counts at Week 12. Although the full details will 
be presented in SAP the Multiple imputat ion will involve 4 principal tasks: 
06 October 2016 Page 40 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
1. Calculate the number of missing values (nmi ss) for absolute change in lesion count. 
2. Missing values will be filled in ‘5 x nmiss’ tim es to generate ‘5 x nmiss’ complete data 
sets. The imputation model used will be an  ANCOVA with factors of treatment group and 
analysis center, and a covariate of baseline le sion count (ie, the imputation model will be 
the same as the analysis model). Appropriate modifications will be made should the 
analysis be based on a non-parametric method. 
3. Each complete data set will be  analyzed with an ANCOVA with factors of treatment group, 
and analysis center, and a covariate of baseline lesion count. 
4. Results from these analyses will be combined into a single inference. 
Sensitivity analyses for IGA  
The first sensitivity analysis for the dichotom ized IGA success will use a repeated measures 
logistic regression model (generalized estimating equations), with dichotomized IGA success as 
the dependent variable and trea tment, analysis center, and visit (ie, Week 4, Week 8) as 
independent factors. In this anal ysis, data from all post-baseline visits will be included with no 
imputation for missing data. 
The second sensitivity analysis will use the m odel based multiple imputation method to impute 
missing data for the dichotomized IGA data. Although the full details will be presented in SAP, 
the multiple imputation will involve 4 principal tasks: 
1. Calculate the number of missing values (nmi ss) for absolute change in lesion count. 
2. Missing values will be filled in ‘5 x nmiss’ tim es to generate ‘5 x nmiss’ complete data 
sets. The imputation model used logistic re gression with factors of treatment group and 
analysis center (ie, the imputation model wi ll be the same as the analysis model). 
3. Each complete data set will be analyzed with  a logistic regression a factors of treatment 
group and analysis center. 
4. Results from these analyses will be combined into a single inference. 
11.[ADDRESS_1200024] ied 80% to 120% of the expected number of 
applications while enro lled in the study.  
11.[ADDRESS_1200025] udy will be recorded and classi fied on the basis of Medical 
Dictionary for Regulatory Activities (Med DRA) terminology. Treatment-emergent AEs 
(TEAEs) are defined as AEs with an onset on or after the date of the fi rst study drug application. 
Adverse events noted prior to the first study dr ug administration that wo rsen after baseline will 
also be reported as AEs and included in the summaries.  
All information pertaining to an AE noted during the study will be listed by [CONTACT_1130], detailing 
verbatim term given by [CONTACT_978] [INVESTIGATOR_1461], preferred term, system organ class (SOC), onset date, 
resolution date, severity, seriousness, action ta ken, outcome and drug relatedness. The event 
onset will also be shown rela tive (in number of days) to date of first application.  
Treatment-emergent AEs will be summarized by [CONTACT_1570], the number of subjects 
reporting a TEAE, SOC, preferred term, severit y, relationship to study drug (causality), and 
seriousness. When summarizing AEs by [CONTACT_42564], each su bject will be counted 
once within a system organ class or a preferred te rm by [CONTACT_294734] w ithin each classification. 
Serious AEs will be summarized by [CONTACT_17673], severity and relationship to study drug, and 
individual SAEs will be listed by [CONTACT_1130]. In addition, a list of subjects who prematurely 
discontinue from the study due to an AE will be provided. 
11.12 Local Skin Reactions 
Local Skin Reactions (LSRs) in clude erythema, peeling, dryness,  burning/stinging and pruritus. 
These will be scored as 0 (None), 1 (Mild),  2 (Moderate) or 3 (Severe). LSRs will be 
summarized by [CONTACT_294735] s. A by-subject listing of 
subjects with any LSR [ADDRESS_1200026] 
listing. 
06 October 2016 Page 42 Confidential 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
Descriptive statistics by [CONTACT_294736]: heart rate (HR), RR duration, QR S duration, PR duration, QT duration and QTc 
duration. Change from Baseline in ECG abnormali ties will be summarized using shift tables at 
the Week [ADDRESS_1200027] at alpha = 0.05. 
For inflammatory lesion change a sample size of [ADDRESS_1200028] 95% power to de tect a statistically 
significant difference with a signi ficance level of 0.[ADDRESS_1200029] deviation of 11.00. 
For non-inflammatory lesion change a sample size of 450 Olumacostat  Glasaretil Gel and 
225 Olumacostat Glasaretil Gel Vehicle subjects  has 95% power to detect a statistically 
significant difference with a signi ficance level of 0.[ADDRESS_1200030] deviation of 16.72. 
The success rate for dichotomized IGA is estimat ed to be 20.5% in the 5.0% BID subjects and 
9.6% in vehicle subjects. A sample size of [ADDRESS_1200031] 95% power to detect a statistically significant difference in 
proportions of successes. These calculations were  performed with nQuery Advisor Version 7.[ADDRESS_1200032]  at alpha = 0.05. 
To allow for a slight loss in power due to dropou ts and withdrawals as well as to accommodate 
sufficient power in all th ree co-primary variables, a sample of 700 subjects randomized to 2 to 1 
for Olumacostat Glasaretil Gel (n=467) and vehicle (n=233), respectively, will be enrolled in the 
trial. 
[ADDRESS_1200033] be 
prepared by [CONTACT_1034]. The Investigator will no t implement any deviation or change to the 
protocol without prior review and documented a pproval/favorable opi[INVESTIGATOR_5698]/EC of 
an Amendment, except where neces sary to eliminate an immediat e hazard(s) to study subjects. 
Any significant deviation must be documented and submitted to the: IRB/EC; the Sponsor or 
designee; and, if required, Regulatory Authority (ies). 
Documentation of approval signed by [CONTACT_294737](s)/EC(s) must be 
sent to the Sponsor and/or designee. 
12.2 Informed Consent Procedures 
The Informed Consent Form (ICF) and Assent Forms for subjects under legal adult age must 
include all elements required by [CONTACT_12212]/GCP and applicable regulatory requirements, and must 
adhere to GCP and to the ethical principles that have their origin  in the Declaration of Helsinki. 
For subjects under legal adult age, both parents or legal representative ma y be required to sign 
informed consent as applicable. Assent to particip ate in a clinical trial ap plies to all subjects who 
are not legal adult subjects (in th e state or location in which they are participating) and is defined 
as a child’s affirmative agreement to participat e in research. Permission of the minor subject’s 
parent or legal guardian must also  be obtained in compliance with part 50, subpart B of the Code 
of Federal Regulations and must include the el ements of informed consent as described in 
Section 50.55 [ 15] and according to the regulations  where the study is being conducted. 
Appropriate ICFs and assent forms will be provided according to local law/regulations. If a 
subject reaches legal adult age during the course  of the trial, an adult ICF will be signed.  
The ICF and Assent Forms must also include a statement that the Sponsor and regulatory 
authorities have direct access to subject re cords. Prior to the beginning of the study, the 
Investigator must have the I RB/EC’s written approval/favorable  opi[INVESTIGATOR_248426], 
Assent Forms and any other information to be provided to the subjects. 
The Investigator must provide th e subject or legally acceptable representative with a copy of the 
consent form and written information about the study in the language in which the subject is 
most proficient. The language must be nontech nical and easily understood. The Investigator 
should allow time necessary for subject or subject’ s legally acceptable repr esentative to inquire 
about the details of the study, then the ICF must be signed and personally dated by [CONTACT_294738]’s legally acceptable representative,  by [CONTACT_294739]. The subject or legally 
acceptable representative should receive a c opy of the signed ICF and any other written 
information provided to study subj ects prior to subjects participation in the study. This also 
applies to Assent Forms. All subjects and/or th e legally acceptable representative (i.e., parents or 
guardian) will be provided with a contact [CONTACT_294740]. 
[ADDRESS_1200034]'s 
legally acceptable representative, should be revised whenever important new information 
becomes available that is relevant to the subjects consent, and should receive IRB/EC approval/ 
favorable opi[INVESTIGATOR_143197]. Th e Investigator or designee should fully inform the subject or the 
subject's legally acceptable representative of a ll pertinent aspects of the study and of any new 
information relevant to the subjects willingne ss to continue participation in the study. This 
communication to the subject should be documented in the source documents.  
During a subject’s participation in the study, any updates to the c onsent or assent forms and any 
updates to the written information will be provided to the subject. 
12.[ADDRESS_1200035]’s medical records or source 
documents. The Investigator is to ensure that th e observations and findings are recorded correctly 
and completely. 
All Investigator observations/assessm ents must be reported in the eCRF. The original reports and 
any traces and films must be reviewed, signed and dated and retained by [CONTACT_294741]. The Investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observat ions and other data pertinen t to the investigation on each 
individual treated with the investigational produc t or entered as a contro l in the investigation. 
Data reported in the eCRFs that are derived from  source documents must be  consistent with the 
source documents or the discrepancies must be explained. The Investigator must certify that the data are co mplete and accurate at the time the subject ends 
the study or as instructed by [CONTACT_294742]. 
12.[ADDRESS_1200036] and visit the Investigat ors at regular intervals through out the study. The study monitor 
will verify adherence to the protocol and comple teness, consistency and accuracy of the data by 
[CONTACT_294743]’ medical r ecords with entries in the eCRF. The study monitor must be 
allowed access to laboratory test reports and other subject records that are needed to verify the 
entries on the eCRF. The Investigators will allow the study monitor to inspect the various records 
of the study (eCRFs and other pertin ent data), provided that subject  confidentiality is maintained 
in accordance with local requirements. These r ecords, and other relevant data, may also be 
reviewed by [CONTACT_294744] d personnel independent from the Sponsor or designee, who is 
appointed to audit the study. Subject confidentiality will be  maintained at all times. 
The Investigators agree to co-operate with th e study monitor to ensure that any problems 
detected in the course of the monitoring visits are resolved. 
[ADDRESS_1200037] the Sponsor prior to destr oying any records associated with 
the study. 
If the Investigator withdraws from the study (e .g., relocation, retirement), the records will be 
transferred to a mutually agreed upon desi gnee (e.g., another Invest igator, IRB/Ethics 
Committee). Notice of such transfer will be gi ven in writing to the Sponsor or designee. 
If the Investigator cannot guarantee this archiving requirement for any or all the documents at the 
investigational site, arra ngements must be made between the Investigator and the Sponsor, to 
store these in a secure archive facility outside the site; they can therefore be returned to the 
Investigator in case of a regulatory audit. Wher e source documents are required for the continued 
care of the subject, appropriate copi[INVESTIGATOR_294712] r storing outside the site. 
Following the study close-out visit da ta will be provided to the I nvestigator to store with the 
Investigator’s study file  for archiving purposes. 
[ADDRESS_1200038] of those commonly used in Dermira study 
documents. Not all acronyms listed belo w are used within this document. 
Abbreviation Definition 
ACC acetyl-coenzyme A carboxylases 
AE adverse event(s) 
ALT alanine amino-transferase 
ANCOVA analysis of covariance 
AR adverse reaction(s) 
AST aspartate amino-transferase 
BID twice daily 
BUN blood urea nitrogen 
CFR code of federal regulations 
CMH Cochran-Mantel-Haenszel 
CRO clinical research organization 
eCRF electronic case report form 
ET early termination 
F Fahrenheit 
[ADDRESS_1200039] hematocrit 
HGB hemoglobin 
ICF informed consent form 
ICH International Conference on Harmonization  
IEC independent ethics committee 
IGA Investigator’s global assessment 
IRB institutional review board 
ITT intent-to-treat 
IV Intravenous 
LDH lactate dehydrogenase 
LOCF last observation carried forward 
LSR local skin reactions 
MCH mean corpuscular hemoglobin 
MCHC mean corpuscular hemoglobin concentration 
MCV mean corpuscular volume 
MedDRA medical dictionary for regulatory activities 
NSAID non-steroidal anti-inflammatory drug 
PP per protocol 
QD once daily 
RBC red blood cells 
SAS statistical analysis software 
SSAR serious suspected adverse reaction(s) 
TG Triglycerides 
TK toxicokinetic  
UPT urine pregnancy test 
US united states 
WBC white blood cells 
WOCBP women of childbearing potential 
β-hCG beta-human chorionic gonadotropin 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
[ADDRESS_1200040] Dermatol. 2004;123:1–12. 
2. Janiczek-Dolphin N, Cook J, Thiboutot D, Harness J, Clucas A. Can sebum reduction 
predict acne outcome? Br J Dermatol. 2010;163:683–688. 
3. Nelson AM, Zhao W, Gilliland KL, Zaenglei n AL, Liu W, Thiboutot DM. Neutrophil 
gelatinase-associated lipocalin mediates 13- cis retinoic acid-induced apoptosis of human 
sebaceous gland cells. J Clin Invest. 2008;118:1468–1478. 
4. Tong L, Harwood HJ Jr. Acetyl-coenzyme A carboxylases: versatile  targets for drug 
discovery. J Cell Bioc hem. 2006;99(6):1476–1488. 
5. Kim KH. Regulation of mammalian acetyl-c oenzyme A carboxylase. Annu Rev Nutr. 
1997;17:77–99. 
6. Harwood HJ Jr. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. 
Expert Opin Ther Targets. 2005;9(2):267–281. 
7. Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target 
for drug discovery. Cell Mol Life Sci. 2005;62(16):1784–1803. 
8. McGarry JD, Brown NF. The mitochondrial car nitine palmitoyltransferase system. From 
concept to molecular analysis. Eur J Biochem. 1997;244(1):1–14. 
9. McCune SA, Harris RA. Mechanism responsib le for 5-(tetradecyloxy)-2-furoic acid 
inhibition of hepatic lipogenesis. J Biol Chem. 1979;254:[ZIP_CODE]–[ZIP_CODE]. 
10. Arbeeny CM, Meyers DS, Bergquist KE, Gre gg RE. Inhibition of fatty acid synthesis 
decreases very low density lipoprotein secretion in the hamster. J Lipid Res. 1992;33(6):843–851. 
11. Parker RA, Kariya T, Grisar JM, Petrow V. 5-(Tetradecyloxy)-2-furancarboxylic acid and related hypolipi[INVESTIGATOR_294713]-like al kyloxyarylcarboxylic acids. J Med Chem. 
1977;20:781–91. 
12. Fukuda N, Ontko JA. Interactions betw een fatty acid synthesis, oxidation, and 
esterification in the production of triglyceride-rich lipoproteins by [CONTACT_4852]. J Lipid Res. 
1984;25(8):831–842. 
13. Triscari J, Sullivan AC. Anti-obesity activity of  a novel lipid synthesis inhibitor. Int J Obes. 
1984;[ADDRESS_1200041] 1:227–239. 
14. Zar, JH (1984), Bios tatistical analysis, 2
nd ed. Englewood Cliffs, New Jersey: P 118-119 
15. 21 CFR §50.55.
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
06 October 2016 Page 49 Confidential 15 APPENDIX 1 – SCHEDULE OF EVENTS  
Visit Screening
Day 
-35 to -1 Baseline/
Day 1 Week 1 
(+/- 2 day) Phone 
Contact 
[CONTACT_10585] 4 
(+/- 4 days) Week 8 
(+/- 4 days) Exit / Early 
Termination 
Week 2  
(+/- 2 day) Week 12 
(+/- 4 days) / ET 
Informed Consent/Assent X       
Demography X       
Medical History X       
Inclusion/Exclusion Criteria X X      
Complete Physical Exam, Heightc, Weight X      X 
Symptom-directed Physical Exam  X X  X X  
Vital Signs X X X  X X X 
Adverse Events  Xa X X X X X 
Local skin reactions  X X  X X X 
Concomitant Medications X X X X X X X 
12-Lead ECGs X      X 
Safety labs: Serum Chemistry, Hematology, 
Serum Pregnancy, Urinalysis X      X  
Urine Pregnancy Test   X   X X  
Investigator Global Assessment  X   X X X 
Acne Patient Self-Questionnaire  X   X X X 
Acne Lesion Counts  X   X X X 
Photographsb  X   X X X 
Dispense Study Medication/Diary  X X  X X  
Study Medication Compliance   X  X X X 
a AEs to be collected after the first dose of study drug is applied. 
b Selected sites only. 
c  Height not required at Week 12. 
Dermira, Inc.  
Olumacostat Glasaretil Gel  DRM01B-ACN04 
16 APPENDIX 2 – ACNE PATIENT SELF- QUESTIONNAIRE  
1. Over the past 7 days, rate how oily your face looked: 
• Asked at BL, wk 4, 8, 12, and OLE 12, 24, [ADDRESS_1200042] 7 days, rate how your face looked overall as the result of your acne: 
• Asked at BL, wk 4, 8, 12, and OLE 12, 24, 36 
 
 0 1 2 3 4 5 6 7 8 9 10 
            Bad                   Excellent 
3. Overall, how would you rate your acne now  as compared to before starting the study 
treatment? 
• Only asked at wk 4, 8, 12, and OLE 12, 24, [ADDRESS_1200043] your face looks 
because of your facial acne? • Asked at BL, wk 4, 8, 12, and OLE 12, 24, [ADDRESS_1200044] your face looks 
because of your facial acne? 
• Asked at BL, wk 4, 8, 12, and OLE 12, 24, [ADDRESS_1200045] 7 days, how often  did you avoid interactions with other people because 
of your facial acne? • Asked at BL, wk 4, 8, 12, and OLE 12, 24, [ADDRESS_1200046] your face looked 
because of your facial acne? • Asked at BL, wk 4, 8, 12, and OLE 12, 24, [ADDRESS_1200047] your face looked because of you 
facial acne? • Asked at BL, wk 4, 8, 12, and OLE 12, 24, [ADDRESS_1200048] o ber 2 0 1 6 Pa ge 5 2 C o nfi de ntial O n a scale of 1 t o 5 ( 1 = Very u ns atisfie d, 5 = Very s atisfie d ), h o w satisfie d were y o u 
wit h eac h of t he f oll o wi n g? 
• To be aske d j ust at wk 1 2 
 1 – V er y  
U ns atisfi e d  2 – 
U ns atisfi e d  3 –   
N e utr al  4 – 
S atisfi e d  5 – V er y  
S atisfi e d  
9. E as e  of  pr o d uct  a p plic ati o n           
[ADDRESS_1200049]  fits  i nt o  
m y  d ail y  s ki n  c ar e  r o uti n e           
 